Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:287-294

This Article
Right arrow Full Text
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Helgadottir, A.
Right arrow Articles by Thorgeirsson, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Helgadottir, A.
Right arrow Articles by Thorgeirsson, G.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*HISTAMINE
*L-TYROSINE
(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:287-294.)
© 1997 American Heart Association, Inc.


Articles

A Role for Tyrosine Phosphorylation in Generation of Inositol Phosphates and Prostacyclin Production in Endothelial Cells

Anna Helgadottir; Haraldur Halldorsson; Kristin Magnusdottir; Matthias Kjeld; Gudmundur Thorgeirsson

the Department of Pharmacology, University of Iceland, Reykjavik (A.H., H.H., K.M., G.T.); and the Departments of Medicine (H.H., G.T.) and Clinical Chemistry (M.K.), Landspitalinn, University Hospital, Reykjavik, Iceland.

Correspondence to Gudmundur Thorgeirsson, Department of Pharmacology, University of Iceland, PO Box 8216, 128 Reykjavik, Iceland.

We have examined the effects of the protein tyrosine phosphatase inhibitor pervanadate on activation of signal transduction in human umbilical vein endothelial cells. Endothelial cells responded to pervanadate treatment by increasing tyrosine phosphorylation of cellular proteins, including phospholipase C (PLC) {gamma}1, generating inositol phosphates (IPs), releasing arachidonic acid, and producing prostacyclin (prostaglandin [PG] I2). The dose and time responses for these events were similar. Tyrosine phosphorylation and formation of IPs in response to pervanadate were reduced by both staurosporine and genistein. Short-term incubation with the phorbol ester 12-O-tetradecanoylphorbol 13-acetate, which inhibits thrombin-induced IP generation, did not affect the IP response to pervanadate. To investigate the possible involvement of tyrosine phosphorylation in thrombin or histamine-induced IP generation and PGI2 production, we examined the effects of costimulation with pervanadate and either thrombin or histamine. These responses proved to be different. While the tyrosine phosphorylation of PLC{gamma}1 was enhanced after cotreatment with thrombin and pervanadate compared with pervanadate alone, costimulation with pervanadate and histamine resulted in no more tyrosine phosphorylation of PLC{gamma}1 than after pervanadate alone. Similarly, while cotreatment with pervanadate and thrombin caused synergistic increase in IP generation, costimulation with pervanadate and histamine resulted in an additive response. However, PGI2 responses to costimulation of pervanadate with either thrombin or histamine were both synergistic. Furthermore, stimulation with histamine, thrombin, or pervanadate all caused tyrosine phosphorylation of a mitogen-activated protein kinase (ERK1/p44). The results suggest that a tyrosine phosphorylation–dependent mechanism has a role in the phosphoinositide signal transduction pathway of human endothelial cells. Moreover, thrombin- but not histamine-induced generation of IPs appears to be partly caused by tyrosine phosphorylation of PLC{gamma}1.


Key Words: endothelial cells • tyrosine phosphorylation • inositol phosphates • prostacyclin • PLC{gamma}1




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
K. Kappert, K. G. Peters, F. D. Bohmer, and A. Ostman
Tyrosine phosphatases in vessel wall signaling
Cardiovasc Res, February 15, 2005; 65(3): 587 - 598.
[Abstract] [Full Text] [PDF]


Home page
Vasc MedHome page
D. Prabhakaran and S. S Anand
The metabolic syndrome: an emerging risk state for cardiovascular disease
Vascular Medicine, February 1, 2004; 9(1): 55 - 68.
[Abstract] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
H.-L. Xu, D. L. Feinstein, R. A. Santizo, H. M. Koenig, and D. A. Pelligrino
Agonist-specific differences in mechanisms mediating eNOS-dependent pial arteriolar dilation in rats
Am J Physiol Heart Circ Physiol, January 1, 2002; 282(1): H237 - H243.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
V. Natarajan, W. M. Scribner, A. J. Morris, S. Roy, S. Vepa, J. Yang, R. Wadgaonkar, S. P. M. Reddy, J. G. N. Garcia, and N. L. Parinandi
Role of p38 MAP kinase in diperoxovanadate-induced phospholipase D activation in endothelial cells
Am J Physiol Lung Cell Mol Physiol, August 1, 2001; 281(2): L435 - L449.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
M. Wassler and B. Shur
Clustering of cell surface (beta)1,4-galactosyltransferase I induces transient tyrosine phosphorylation of focal adhesion kinase and loss of stress fibers
J. Cell Sci., January 1, 2000; 113(2): 237 - 245.
[Abstract] [PDF]